Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Nurix (NRIX) PT Lowered to $28 at Needham
January 29, 2025 7:59 AM ESTNeedham analyst Gil Blum lowered the price target on Nurix (NASDAQ: NRIX) to $28.00 (from $29.00) while maintaining a Buy rating.
The analyst comments "Financials and Model Updates. In 2024, Nurix received ~$13M in collaboration revenue from its partners including a $5M milestone... More
